Oncogenic pathway signatures predict the risk of progression and recurrence in well‐differentiated pancreatic neuroendocrine tumors
Journal of Surgical Oncology · 2024
DOI: 10.1002/jso.27830 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2024. Verfasst von Michael A Mederos und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of California Los Angeles, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Neuroendocrine Tumors, Neoplasm Recurrence, Local, Disease Progression. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI/NIH, Hirshberg Foundation for Pancreatic Research, NCI NIH HHS.
Abstract (Originalsprache)
Background
Pancreatic neuroendocrine tumors (pNETs) are genomically diverse tumors. The management of newly diagnosed well‐differentiated pNETs is limited by a lack of sensitivity of existing biomarkers for prognostication. Our goal was to investigate the potential utility of genetic markers as a predictor of progression‐free survival (PFS) and recurrence‐free survival (RFS).
Methods
Whole‐exome sequencing of resected well‐differentiated, low and intermediate‐grade (G1 and G2) pNETs and normal adjacent tissue from patients who underwent resection from 2005 to 2015 was performed. Genetic alterations were classified using pan‐genomic and oncogenic pathway classifications. Additional samples with genetic and clinicopathologic data available were obtained from the publicly available International Cancer Genome Consortium (ICGC) database and included in the analysis. The prognostic relevance of these genomic signatures on PFS and RFS was analyzed.
Results
Thirty‐one patients who underwent resection for pNET were identified. Genomic analysis of mutational, copy number, cytogenetic, and complex phenomena revealed similar patterns to prior studies of pNETs with relatively few somatic gene mutations but numerous instances of copy number changes. Analysis of genomic and clinicopathologic outcomes using the combined data from our study as well as the ICGC pNET cohort ( n = 124 patients) revealed that the recurrent pattern of whole chromosome loss (RPCL) and metastatic disease were independently associated with disease progression. When evaluating patients with local disease at the time of resection, RPCL and alterations in the TGFβ oncogenic pathway were independently associated with the risk of recurrence.
Conclusions
Well‐differentiated pNETs are genomically diverse tumors. Pathway signatures may be prognostic for predicting disease progression and recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, University of California Los Angeles, Los Angeles, California, USA.
- Mays Cancer Center, University of Texas Health San Antonio, San Antonio, Texas, USA.
- Department of Molecular, Cellular, and Integrative Physiology, University of California Los Angeles, Los Angeles, California, USA.
- Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California, USA.
- Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California, USA.
- Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California, USA.
Förderung
- NCI/NIH
- Hirshberg Foundation for Pancreatic Research
- NCI NIH HHS
- W.M. Keck Foundation
Zitieren
APA
Mederos, M. A., Court, C. M., Dipardo, B. J., Pisegna, J. R., Dawson, D. W., Joe Hines, O., Donahue, T. R., Graeber, T. G., Girgis, M. D., & Tomlinson, J. S. (2024). Oncogenic pathway signatures predict the risk of progression and recurrence in well‐differentiated pancreatic neuroendocrine tumors. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27830
Vancouver
Mederos MA, Court CM, Dipardo BJ, Pisegna JR, Dawson DW, Joe Hines O, et al. Oncogenic pathway signatures predict the risk of progression and recurrence in well‐differentiated pancreatic neuroendocrine tumors. Journal of Surgical Oncology. 2024. doi:10.1002/jso.27830
BibTeX
@article{Mederos2024,
author = {Mederos, Michael A and Court, Colin M and Dipardo, Benjamin J and Pisegna, Joseph R and Dawson, David W and Joe Hines, O and Donahue, Timothy R and Graeber, Thomas G and Girgis, Mark D and Tomlinson, James S},
title = {Oncogenic pathway signatures predict the risk of progression and recurrence in well‐differentiated pancreatic neuroendocrine tumors},
journal = {Journal of Surgical Oncology},
year = {2024},
doi = {10.1002/jso.27830}
}
EUVIMED